Although inhibitors of oncogenic BRAF generally exert a temporary therapeutic efficacy in patients with metastatic BRAF-mutated melanoma, recent evidences seem to indicate that subsets of such cases may present a long-term response to single-agent BRAF inhibition (6). This evidence concerns the gene BRAF and melanoma.